Anthracyclines

Name
Anthracyclines
Accession Number
DBCAT000874
Description

Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.

Drugs
DrugDrug Description
ValrubicinAn anthracycline used intravesically in the treatment of BCG-resistant bladder carcinoma.
EpirubicinAn anthracycline topoisomerase II inhibitor used as an adjuvant to treating axillary node metastases in patients who have undergone surgical resection of primary breast cancer.
DaunorubicinAn anthracycline aminoglycoside used to induce remission of nonlymphocytic leukemia and acute lymphocytic leukemia.
DoxorubicinA medication used to treat various cancers and Kaposi's Sarcoma.
IdarubicinAn anthracycline antineoplastic agent used to treat acute myeloid leukemia (AML) in adults.
AldoxorubicinInvestigated for use/treatment in solid tumors.
AnnamycinInvestigated for use/treatment in breast cancer and leukemia (unspecified).
PlicamycinFor the treatment of testicular cancer, as well as hypercalcemia and hypercalciuria associated with a variety of advanced forms of cancer.
PirarubicinNot Annotated
AclarubicinNot Annotated
ZorubicinZorubicin is a drug of the anthracycline class - a class of medications that have historically demonstrated effective chemotherapy for a variety of cancer types.
SabarubicinSabarubicin has been used in trials studying the treatment of Prostate Cancer, Testicular Germ Cell Tumor, and Unspecified Adult Solid Tumor, Protocol Specific.
Zoptarelin doxorubicinZoptarelin doxorubicin has been used in trials studying the treatment of Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, and Urothelial Carcinoma, among others.
GPX-150GPX-150 has been used in trials studying the treatment of Soft Tissue Sarcoma and Advanced Solid Tumors - Phase 1 Population.
SP1049CIntended for the treatment of carcinoma of the oesophagus.
DTS-201Investigated for use/treatment in cancer/tumors (unspecified).
GancotamabGancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).
Drugs & Drug Targets
DrugTargetType
ValrubicinDNA topoisomerase 2-alphatarget
ValrubicinDNAtarget
EpirubicinDNA topoisomerase 2-alphatarget
EpirubicinDNAtarget
EpirubicinMultidrug resistance-associated protein 1transporter
EpirubicinUDP-glucuronosyltransferase 2B7enzyme
EpirubicinCytosolic phospholipase A2enzyme
DaunorubicinDNAtarget
DaunorubicinXanthine dehydrogenase/oxidaseenzyme
DaunorubicinCytochrome P450 3A5enzyme
DaunorubicinNADPH--cytochrome P450 reductaseenzyme
DaunorubicinP-glycoprotein 1transporter
DaunorubicinMultidrug resistance-associated protein 1transporter
DaunorubicinCanalicular multispecific organic anion transporter 1transporter
DaunorubicinMultidrug resistance-associated protein 6transporter
DaunorubicinBile salt export pumptransporter
DaunorubicinMultidrug resistance-associated protein 7transporter
DaunorubicinATP-binding cassette sub-family G member 2transporter
DaunorubicinDNA topoisomerase 2-alphatarget
DaunorubicinDNA topoisomerase 2-betatarget
DaunorubicinCytochrome P450 1A1enzyme
DaunorubicinCytochrome P450 1B1enzyme
DaunorubicinCytochrome P450 3A4enzyme
DoxorubicinDNA topoisomerase 2-alphatarget
DoxorubicinDNAtarget
DoxorubicinCytochrome P450 3A4enzyme
DoxorubicinCytochrome P450 2D6enzyme
DoxorubicinCytochrome P450 2B6enzyme
DoxorubicinP-glycoprotein 1transporter
DoxorubicinCanalicular multispecific organic anion transporter 2transporter
DoxorubicinMultidrug resistance-associated protein 6transporter
DoxorubicinMultidrug resistance-associated protein 1transporter
DoxorubicinMultidrug resistance-associated protein 7transporter
DoxorubicinATP-binding cassette sub-family G member 2transporter
DoxorubicinBile salt export pumptransporter
DoxorubicinSolute carrier family 22 member 16transporter
DoxorubicinATP-binding cassette sub-family B member 8, mitochondrialtransporter
DoxorubicinCytochrome P450 1B1enzyme
DoxorubicinCarbonyl reductase [NADPH] 1enzyme
DoxorubicinCarbonyl reductase [NADPH] 3enzyme
DoxorubicinAlcohol dehydrogenase [NADP(+)]enzyme
DoxorubicinAldo-keto reductase family 1 member C3enzyme
DoxorubicinNAD(P)H dehydrogenase [quinone] 1enzyme
DoxorubicinXanthine dehydrogenase/oxidaseenzyme
DoxorubicinNitric oxide synthase, endothelialenzyme
DoxorubicinNitric oxide synthase, inducibleenzyme
DoxorubicinNitric oxide synthase, brainenzyme
DoxorubicinNADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrialenzyme
DoxorubicinNADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrialenzyme
DoxorubicinNADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrialenzyme
DoxorubicinNADPH--cytochrome P450 reductaseenzyme
DoxorubicinRalA-binding protein 1transporter
DoxorubicinCanalicular multispecific organic anion transporter 1transporter
DoxorubicinSerum albumincarrier
DoxorubicinNucleolar and coiled-body phosphoprotein 1target
IdarubicinDNA topoisomerase 2-alphatarget
IdarubicinDNAtarget
IdarubicinMultidrug resistance-associated protein 1transporter
IdarubicinCytochrome P450 2C9enzyme
IdarubicinCytochrome P450 2D6enzyme
AldoxorubicinDNA topoisomerase 2-alphatarget
AnnamycinDNA topoisomerase 2-alphatarget
AnnamycinDNAtarget
AnnamycinP-glycoprotein 1transporter
PlicamycinDNAtarget
SP1049CDNA topoisomerase 2-alphatarget